Literature DB >> 7893584

Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness.

T S Trovik1, R Jaeger, R Jorde, G Sager.   

Abstract

Nine IDDM-patients with hypoglycaemia unawareness, seven IDDM-patients with hypoglycemia awareness and a control group of nine healthy persons were included in this study. The patients were recruited from the medical out-patients' department of the University Hospital of Tromsø. The pathophysiological changes which cause hypoglycaemia unawareness are today not clear. Reduced peripheral tissue sensitivity to catecholamines is suggested as one of several mechanisms which may contribute. For further investigation of beta-adrenergic sensitivity an isoprenaline/metoprolol sensitivity test was performed. Isoprenaline and metoprolol were administered intravenously, and the effects on heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP) and plasma levels of adrenaline (ADR) and noradrenaline (NA) were measured. All subjects were given the same doses of isoprenaline (0.25-8 micrograms) and metoprolol (0.5-8 mg). Metoprolol was given together with the dose of isoprenaline which increased heart rate by 25 beats min-1. The dose/response curves of both isoprenaline/HR and metoprolol/HR were significantly shifted to the right in IDDM-patients with hypoglycaemia unawareness compared with controls and IDDM-patients with hypoglycaemia awareness (P < 0.05). Reduced sensitivity of isoprenaline stimulation has also been shown before, whereas reduced sensitivity of a blocking agent has not earlier been shown. These findings support the hypothesis of reduced beta-adrenergic sensitivity as one pathophysiological component in hypoglycaemia unawareness.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893584      PMCID: PMC1364876          DOI: 10.1111/j.1365-2125.1994.tb04378.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Hypoglycemic symptoms and decreased beta-adrenergic sensitivity in insulin-dependent diabetic patients.

Authors:  I Berlin; A Grimaldi; C Payan; C Sachon; F Bosquet; F Thervet; A J Puech
Journal:  Diabetes Care       Date:  1987 Nov-Dec       Impact factor: 19.112

2.  Lack of hypoglycemic symptoms and decreased beta-adrenergic sensitivity in insulin-dependent diabetic patients.

Authors:  I Berlin; A Grimaldi; C Landault; F Zoghbi; F Thervet; A J Puech; J C Legrand
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958

3.  Intravenously administered isoproterenol sulfate dose-response curves in man.

Authors:  C F George; M E Conolly; T Fenyvesi; R Briant; C T Dollery
Journal:  Arch Intern Med       Date:  1972-09

4.  Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes.

Authors:  D C Simonson; W V Tamborlane; R A DeFronzo; R S Sherwin
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

5.  Decreased beta-adrenergic sensitivity in insulin-dependent diabetic subjects.

Authors:  I Berlin; A Grimaldi; F Bosquet; A J Puech
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

6.  Impaired counter regulation of hypoglycemia in a group of insulin-dependent diabetics with recurrent episodes of severe hypoglycemia.

Authors:  U Adamson; P E Lins; S Efendic; B Hamberger; A Wajngot
Journal:  Acta Med Scand       Date:  1984

7.  Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy.

Authors:  R D Hoeldtke; G Boden; C R Shuman; O E Owen
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

8.  Determination of metoprolol and two major metabolites in plasma and urine by column liquid chromatography and fluorometric detection.

Authors:  K Balmér; Y Y Zhang; P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1987-07-03

9.  Standardised isoprenaline sensitivity tests--a comparison of existent methods.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

10.  Mononuclear leukocyte beta 2-adrenergic receptors and adenylate cyclase sensitivity in insulin-dependent diabetes mellitus.

Authors:  P Sérusclat; S G Rosen; E B Smith; S D Shah; W E Clutter; P E Cryer
Journal:  Diabetes       Date:  1983-09       Impact factor: 9.461

View more
  6 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Dysfunction in the beta 2-adrenergic signal pathway in patients with insulin dependent diabetes mellitus (IDDM) and unawareness of hypoglycaemia.

Authors:  T S Trovik; A Vaartun; R Jorde; G Sager
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Protein kinase C modulation of the regulation of sarcoplasmic reticular function by protein kinase A-mediated phospholamban phosphorylation in diabetic rats.

Authors:  Satoko Watanuki; Naoyuki Matsuda; Fumika Sakuraya; Subrina Jesmin; Yuichi Hattori
Journal:  Br J Pharmacol       Date:  2003-12-22       Impact factor: 8.739

4.  The effect of antecedent hypoglycaemia on β₂-adrenergic sensitivity in healthy participants with the Arg16Gly polymorphism of the β₂-adrenergic receptor.

Authors:  B J J W Schouwenberg; P Smits; C J Tack; B E de Galan
Journal:  Diabetologia       Date:  2011-02-06       Impact factor: 10.122

5.  Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy.

Authors:  Alok S Tripathi; Papiya M Mazumder; Anil V Chandewar
Journal:  J Diabetes Metab Disord       Date:  2014-01-07

Review 6.  Expression and Signaling of β-Adrenoceptor Subtypes in the Diabetic Heart.

Authors:  Betul R Erdogan; Martin C Michel; Ebru Arioglu-Inan
Journal:  Cells       Date:  2020-11-26       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.